Pancreatic Cancer Research

Clinical trialPhase 1Completed

Clinical Trial of Metastasis Inhibitor NP-G2-044 in Patients With Advanced or Metastatic Treatment-Refractory Solid Tumor Malignancies

First-in-Human, Dose Finding, Open Label Phase 1A-1B Clinical Trial of Metastasis Inhibitor NP-G2-044 in Patients With Advanced or Metastatic Treatment-Refractory Solid Tumor Malignancies

Outcome
Finished, no results posted
Phase
Phase 1
Status
Completed
Study type
Interventional
Start
21 December 2017
Ended
7 May 2020
Enrollment
23 participants
Sites
3
Primary outcomes
Establish the safe recommended phase 2 dose
Sponsor type
Industry
Results posted
No
Last update
20 July 2025

These fields come from the trial’s registry entry. A summary of its population, design, endpoints and results, each tied to a quote, has not been written for this trial yet.

Ask this document

Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.

Try

Source text

Brief summary public domain (ClinicalTrials.gov)

Phase 1 A: First-in-human phase 1 study to determine safety of NP-G2-044 when given orally on a daily X 28 days followed by a 14 day rest period.